Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma

Stephen Spurgeon, Talia Pindyck, Craig Okada, Yiyi Chen, Zunqiu Chen, Elana Mater, Kamal Abbi, Elliot M. Epner

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma that is incurable with standard chemotherapy. There is no consensus on the best initial therapy, especially for elderly patients, who are not candidates for aggressive treatment approaches. Current National Comprehensive Cancer Network (NCCN) treatment guidelines include rituximab (R) plus cladribine for the initial treatment of MCL. However, few data are available to substantiate this recommendation. Therefore, to further define the role of R-cladribine for the initial treatment of MCL, we performed a retrospective chart review of 31 patients with MCL (median age, 67) treated with R-cladribine. The majority of responding patients also received R maintenance. The overall response rate was 87%, with 61% of patients achieving a complete remission (CR/CRu). The estimated median follow-up was 32.5 months, median PFS was 37.5 months, and median OS was 85.2 months. One of 19 (5.3%) subjects in CR/CRu relapsed (median follow-up of 23 months). CR/CRu was associated with improved survival (p <0.0001), while a high mantle cell international prognostic index (MIPI) was associated with worse survival (p = 0.05). There was one toxic death (neutropenic pseudomonal sepsis) related to treatment. R-cladribine is an effective therapy for previously untreated MCL, and these results validate the use of R-cladribine for the initial treatment of MCL.

Original languageEnglish (US)
Pages (from-to)1488-1494
Number of pages7
JournalLeukemia and Lymphoma
Volume52
Issue number8
DOIs
StatePublished - Aug 2011

Fingerprint

Cladribine
Mantle-Cell Lymphoma
Therapeutics
Survival
Rituximab
Poisons
Non-Hodgkin's Lymphoma
Sepsis
Maintenance
Guidelines
Drug Therapy

Keywords

  • cladribine
  • Mantle cell lymphoma
  • response
  • rituximab

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. / Spurgeon, Stephen; Pindyck, Talia; Okada, Craig; Chen, Yiyi; Chen, Zunqiu; Mater, Elana; Abbi, Kamal; Epner, Elliot M.

In: Leukemia and Lymphoma, Vol. 52, No. 8, 08.2011, p. 1488-1494.

Research output: Contribution to journalArticle

Spurgeon, Stephen ; Pindyck, Talia ; Okada, Craig ; Chen, Yiyi ; Chen, Zunqiu ; Mater, Elana ; Abbi, Kamal ; Epner, Elliot M. / Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. In: Leukemia and Lymphoma. 2011 ; Vol. 52, No. 8. pp. 1488-1494.
@article{0e7436efe0e0425583bf4d6636fbec96,
title = "Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma",
abstract = "Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma that is incurable with standard chemotherapy. There is no consensus on the best initial therapy, especially for elderly patients, who are not candidates for aggressive treatment approaches. Current National Comprehensive Cancer Network (NCCN) treatment guidelines include rituximab (R) plus cladribine for the initial treatment of MCL. However, few data are available to substantiate this recommendation. Therefore, to further define the role of R-cladribine for the initial treatment of MCL, we performed a retrospective chart review of 31 patients with MCL (median age, 67) treated with R-cladribine. The majority of responding patients also received R maintenance. The overall response rate was 87{\%}, with 61{\%} of patients achieving a complete remission (CR/CRu). The estimated median follow-up was 32.5 months, median PFS was 37.5 months, and median OS was 85.2 months. One of 19 (5.3{\%}) subjects in CR/CRu relapsed (median follow-up of 23 months). CR/CRu was associated with improved survival (p <0.0001), while a high mantle cell international prognostic index (MIPI) was associated with worse survival (p = 0.05). There was one toxic death (neutropenic pseudomonal sepsis) related to treatment. R-cladribine is an effective therapy for previously untreated MCL, and these results validate the use of R-cladribine for the initial treatment of MCL.",
keywords = "cladribine, Mantle cell lymphoma, response, rituximab",
author = "Stephen Spurgeon and Talia Pindyck and Craig Okada and Yiyi Chen and Zunqiu Chen and Elana Mater and Kamal Abbi and Epner, {Elliot M.}",
year = "2011",
month = "8",
doi = "10.3109/10428194.2011.575489",
language = "English (US)",
volume = "52",
pages = "1488--1494",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma

AU - Spurgeon, Stephen

AU - Pindyck, Talia

AU - Okada, Craig

AU - Chen, Yiyi

AU - Chen, Zunqiu

AU - Mater, Elana

AU - Abbi, Kamal

AU - Epner, Elliot M.

PY - 2011/8

Y1 - 2011/8

N2 - Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma that is incurable with standard chemotherapy. There is no consensus on the best initial therapy, especially for elderly patients, who are not candidates for aggressive treatment approaches. Current National Comprehensive Cancer Network (NCCN) treatment guidelines include rituximab (R) plus cladribine for the initial treatment of MCL. However, few data are available to substantiate this recommendation. Therefore, to further define the role of R-cladribine for the initial treatment of MCL, we performed a retrospective chart review of 31 patients with MCL (median age, 67) treated with R-cladribine. The majority of responding patients also received R maintenance. The overall response rate was 87%, with 61% of patients achieving a complete remission (CR/CRu). The estimated median follow-up was 32.5 months, median PFS was 37.5 months, and median OS was 85.2 months. One of 19 (5.3%) subjects in CR/CRu relapsed (median follow-up of 23 months). CR/CRu was associated with improved survival (p <0.0001), while a high mantle cell international prognostic index (MIPI) was associated with worse survival (p = 0.05). There was one toxic death (neutropenic pseudomonal sepsis) related to treatment. R-cladribine is an effective therapy for previously untreated MCL, and these results validate the use of R-cladribine for the initial treatment of MCL.

AB - Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma that is incurable with standard chemotherapy. There is no consensus on the best initial therapy, especially for elderly patients, who are not candidates for aggressive treatment approaches. Current National Comprehensive Cancer Network (NCCN) treatment guidelines include rituximab (R) plus cladribine for the initial treatment of MCL. However, few data are available to substantiate this recommendation. Therefore, to further define the role of R-cladribine for the initial treatment of MCL, we performed a retrospective chart review of 31 patients with MCL (median age, 67) treated with R-cladribine. The majority of responding patients also received R maintenance. The overall response rate was 87%, with 61% of patients achieving a complete remission (CR/CRu). The estimated median follow-up was 32.5 months, median PFS was 37.5 months, and median OS was 85.2 months. One of 19 (5.3%) subjects in CR/CRu relapsed (median follow-up of 23 months). CR/CRu was associated with improved survival (p <0.0001), while a high mantle cell international prognostic index (MIPI) was associated with worse survival (p = 0.05). There was one toxic death (neutropenic pseudomonal sepsis) related to treatment. R-cladribine is an effective therapy for previously untreated MCL, and these results validate the use of R-cladribine for the initial treatment of MCL.

KW - cladribine

KW - Mantle cell lymphoma

KW - response

KW - rituximab

UR - http://www.scopus.com/inward/record.url?scp=79960400013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960400013&partnerID=8YFLogxK

U2 - 10.3109/10428194.2011.575489

DO - 10.3109/10428194.2011.575489

M3 - Article

C2 - 21623691

AN - SCOPUS:79960400013

VL - 52

SP - 1488

EP - 1494

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 8

ER -